Jaimee L Heffner1, A Eden Evins2, Cristina Russ3, David Lawrence3, Catherine R Ayers4, Thomas McRae3, Lisa St Aubin3, Alok Krishen5, Robert West6, Robert M Anthenelli4. 1. Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, M3-B232; PO Box 19024; Seattle, WA 98109, USA. Electronic address: jheffner@fredhutch.org. 2. Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 3. Pfizer, New York, NY, USA. 4. University of California, San Diego, CA, USA. 5. PAREXEL International on behalf of GlaxoSmithKline, Research Triangle Park, NC, USA. 6. University College, London, UK.
Abstract
OBJECTIVES: Post hoc analyses of EAGLES data to examine safety and efficacy of first-line smoking cessation pharmacotherapies in smokers with bipolar disorders (BD). METHODS: Smokers with BD I/II (n = 285; 81.4% with BD I) and a comparison nonpsychiatric cohort (NPC; n = 2794) were randomly assigned to varenicline, bupropion, nicotine replacement therapy (NRT), or placebo for 12 weeks, plus weekly counseling. Primary outcomes were occurrence of moderate to severe neuropsychiatric adverse events (NPSAEs) and Weeks 9-12 biochemically-confirmed continuous abstinence (CA) rates. RESULTS: For BD smokers, NPSAE risk differences versus placebo were: varenicline, 6.17 (95% CI: -7.84 to 20.18); bupropion, 4.09 (-8.82 to 16.99); NRT, -0.56 (-12.34 to 11.22). ORs for Weeks 9-12 CA, comparing active medication to placebo among BD smokers were: varenicline, 2.61 (0.68-9.95); bupropion, 1.29 (0.31-5.37), NRT, 0.71 (0.14-3.74). Pooling across treatments, NPSAE occurrence was higher (10.7% versus 2.3%; P < 0.001) and CA rates were lower (22.8% versus 13.3%; P = 0.008) in BD than NPC. LIMITATIONS: Study not powered to detect differences in safety and efficacy in the BD subcohort; generalizability limited to stably treated BD without current substance use disorders. CONCLUSIONS: Smokers with BD had higher risk of NPSAEs and were less likely to quit overall than NPC smokers. Among smokers with BD, NPSAE risk difference estimates for active treatments versus placebo ranged from 1% lower to 6% higher. Efficacy of varenicline in smokers with BD was similar to EAGLES main outcomes; bupropion and NRT effect sizes were descriptively lower. Varenicline may be a tolerable and effective cessation treatment for smokers with BD. TRIAL REGISTRATION: ClinicalTrials.gov identifier (https://clinicaltrials.gov/): NCT01456936.
OBJECTIVES: Post hoc analyses of EAGLES data to examine safety and efficacy of first-line smoking cessation pharmacotherapies in smokers with bipolar disorders (BD). METHODS: Smokers with BD I/II (n = 285; 81.4% with BD I) and a comparison nonpsychiatric cohort (NPC; n = 2794) were randomly assigned to varenicline, bupropion, nicotine replacement therapy (NRT), or placebo for 12 weeks, plus weekly counseling. Primary outcomes were occurrence of moderate to severe neuropsychiatric adverse events (NPSAEs) and Weeks 9-12 biochemically-confirmed continuous abstinence (CA) rates. RESULTS: For BD smokers, NPSAE risk differences versus placebo were: varenicline, 6.17 (95% CI: -7.84 to 20.18); bupropion, 4.09 (-8.82 to 16.99); NRT, -0.56 (-12.34 to 11.22). ORs for Weeks 9-12 CA, comparing active medication to placebo among BD smokers were: varenicline, 2.61 (0.68-9.95); bupropion, 1.29 (0.31-5.37), NRT, 0.71 (0.14-3.74). Pooling across treatments, NPSAE occurrence was higher (10.7% versus 2.3%; P < 0.001) and CA rates were lower (22.8% versus 13.3%; P = 0.008) in BD than NPC. LIMITATIONS: Study not powered to detect differences in safety and efficacy in the BD subcohort; generalizability limited to stably treated BD without current substance use disorders. CONCLUSIONS: Smokers with BD had higher risk of NPSAEs and were less likely to quit overall than NPC smokers. Among smokers with BD, NPSAE risk difference estimates for active treatments versus placebo ranged from 1% lower to 6% higher. Efficacy of varenicline in smokers with BD was similar to EAGLES main outcomes; bupropion and NRT effect sizes were descriptively lower. Varenicline may be a tolerable and effective cessation treatment for smokers with BD. TRIAL REGISTRATION: ClinicalTrials.gov identifier (https://clinicaltrials.gov/): NCT01456936.
Authors: Caryn Lerman; Robert A Schnoll; Larry W Hawk; Paul Cinciripini; Tony P George; E Paul Wileyto; Gary E Swan; Neal L Benowitz; Daniel F Heitjan; Rachel F Tyndale Journal: Lancet Respir Med Date: 2015-01-12 Impact factor: 30.700
Authors: Freda Patterson; Michael A Grandner; Susan K Malone; Albert Rizzo; Adam Davey; David G Edwards Journal: Nicotine Tob Res Date: 2019-01-04 Impact factor: 4.244
Authors: Gina F Marrone; Diaa M Shakleya; Karl B Scheidweiler; Edward G Singleton; Marilyn A Huestis; Stephen J Heishman Journal: Addiction Date: 2011-05-27 Impact factor: 6.526
Authors: Faith Dickerson; Catherine R Stallings; Andrea E Origoni; Crystal Vaughan; Sunil Khushalani; Jennifer Schroeder; Robert H Yolken Journal: Psychiatr Serv Date: 2013-01 Impact factor: 3.084
Authors: Andrea H Weinberger; Jennifer C Vessicchio; Kristi A Sacco; Cerissa L Creeden; K N Roy Chengappa; Tony P George Journal: J Clin Psychopharmacol Date: 2008-10 Impact factor: 3.153
Authors: K N Roy Chengappa; Kenneth A Perkins; Jaspreet S Brar; Patricia J Schlicht; Scott R Turkin; Michelle L Hetrick; Michele D Levine; Tony P George Journal: J Clin Psychiatry Date: 2014-07 Impact factor: 4.384
Authors: Jaimee L Heffner; Megan M Kelly; Jeanette Waxmonsky; Kristin Mattocks; Edit Serfozo; Jonathan B Bricker; Kristin E Mull; Noreen L Watson; Michael Ostacher Journal: Nicotine Tob Res Date: 2020-08-24 Impact factor: 4.244
Authors: John B Correa; David Lawrence; Benjamin S McKenna; Natassia Gaznick; Phillip A Saccone; Sarah Dubrava; Neal Doran; Robert M Anthenelli Journal: Nicotine Tob Res Date: 2021-08-29 Impact factor: 4.244